MEDIGENE AG
9-MONTHS REPORT 2014

medigene

MEDIGENE'S KEY FIGURES

IN € K	**Q3 2014 UNAUDITED**	Q3 2013 UNAUDITED	CHANGE	**9M 2014 UNAUDITED**	9M 2013 UNAUDITED	CHANGE
Income statement						
Revenue Veregen®	**1,118**	959	17%	**3,672**	2,837	29%
thereof Veregen® royalties	**729**	646	13%	**1,747**	1,889	-8%
thereof Veregen® revenue from supply chain	**364**	181	101%	**1,200**	735	63%
thereof Veregen® milestone payments	**25**	132	-81%	**725**	213	>200%
Other operating income	**1,166**	954	22%	**4,704**	2,284	106%
thereof income from R&D funding	**468**	309	51%	**1,486**	382	>200%
thereof R&D milestone payments	**14**	6	133%	**742**	7	>200%
thereof other income	**684**	639	7%	**2,476**	1,895	31%
Total revenue	**2,284**	**1,913**	**19%**	**8,376**	**5,121**	**64%**
Cost of sales	**-414**	-228	82%	**-1,212**	-1,055	15%
Gross profit	**1,870**	1,685	11%	**7,164**	4,066	76%
Selling, general and administrative expenses	**-1,742**	-2,011	-13%	**-5,648**	-5,616	1%
Research and development expenses	**-1,975**	-1,673	18%	**-5,383**	-5,119	5%
Operating result	**-1,847**	-1,999	-8%	**-3,867**	-6,669	-42%
Net result for the period	**-2,804**	**-2,072**	**35%**	**-5,644**	**-7,728**	**-27%**
EBITDA	**-1,640**	**-1,815**	**-10%**	**-3,269**	**-6,106**	**-46%**
Earnings per share in €	**-0.21**	-0.21	0%	**-0.49**	-0.81	-40%
Personnel expenses	**-1,706**	-1,318	29%	**-4,973**	-4,256	17%
Cash flow statement						
Cash flow from operating activities	**-1,477**	-3,322	-56 %	**-7,084**	-10,825	-35%
Cash flow from investing activities	**-454**	-11	>200 %	**-842**	-42	>200%
Cash flow from financing activities	**14,635**	-14	–	**14,571**	2,378	>200%
Balance sheet data as at 30 September						
Cash and cash equivalents				**16,689**	11,655	43%
Balance sheet total				**69,203**	54,077	28%
Current liabilities				**4,169**	3,518	19%
Non-current liabilities				**15,606**	11,690	33%
Shareholders' equity				**49,428**	38,869	27%
Equity ratio in %				**71**	72	-1%
Employees as at 30 September				**66**	47	40%
FTE as at 30 September				**57**	44	29%
Medigene share as at 30 September						
Total number of shares outstanding				**13,918,931**	9,872,139	41%
Share price (XETRA closing price)				**4,00**	3,78	6%

MEDIGENE'S PRODUCTS AND CLINICAL PROJECTS

PRODUCT	INDICATION	PRE-CLINIC	CLINICAL PHASE I	CLINICAL PHASE II	CLINICAL PHASE III	APPROV-AL	MARKET
Marketed drugs							
Veregen®	Genital warts						
Immunotherapies under development							
DC vaccines	Prostate cancer[2)]						
DC vaccines	Acute myeloid leukaemia (AML)[2)]						
TCR	Cancer						
TABS	Leukaemia and autoimmune diseases						
AAVLP	Vaccine technology						
Partnered drug candidates							
EndoTAG®-1	Triple-negative breast cancer (TNBC)						
RhuDex®	Autoimmune diseases						
Chance of reaching the market[1)]		< 10 %	< 15 %	< 30 %	< 70 %	< 90 %	

[1)] Industrial average, estimates of Medigene AG

[2)] Investigator-initiated trial, IIT

Content

MEDIGENE'S SHARE PRICE PERFORMANCE

(2 JANUARY 2014 €3.53 INDEXED TO 100)



2 January 2014 30 September 2014

KEY FIGURES OF THE MEDIGENE SHARE

IN €	**9M 2014**	9M 2013
9-months high[1)]	**6.75**	4.40
9-months low[1)]	**3.42**	3.04
Opening price[1)]	**3.53**	4.08
Closing price[1)]	**4.00**	3.78
Average price[1)]	**4.67**	3.76
Weighted average number of shares	**11,633,933**	9,550,484
Average market capitalisation (€ m)	**65**	37
Average daily trading volume (in shares)	**52,080**	14,663
Total number of shares outstanding	**13,918,931**	9,872,139
Earnings per share in €	**-0.49**	-0.81
Shareholders' equity per share[2)]	**3.55**	3.94
Cash flow from operating activities per share[2)]	**-0.51**	-1.10
Free float[3)] (%)	**77**	84

[1)] Reference amount: XETRA

[2)] Reference amount: total number of shares outstanding

[3)] Source: Medigene AG

GROUP INTERIM MANAGEMENT'S DISCUSSION AND ANALYSIS Q3 2014/9M 2014

OF MEDIGENE AG, PLANEGG/MARTINSRIED, GERMANY, FOR THE PERIOD FROM 1 JANUARY TO 30 SEPTEMBER 2014

FINANCIAL HIGHLIGHTS IN THE FIRST HALF OF 2014

- **Total revenue up by 64% to €8,376 k (9M 2013: €5,121 k)**
- **Revenue from Veregen® up by 29% to €3,672 k (9M 2013: €2,837 k)**
- **EBITDA-based loss reduced by 46% to €3,269 k (9M 2013: €-6,106 k)**
- **Loss for the period reduced by 27% to €5,644 k (9M 2013: €-7,728 k)**
- **Increase in cash and cash equivalents from capital measure to €16,689 k (31.12.2013: €10,166 k)**

OPERATING HIGHLIGHTS SINCE THE BEGINNING OF 2014

Companies:

- Acquisition of Trianta Immunotherapies GmbH (now "Medigene Immunotherapies GmbH")
- Appointment of Prof. Dolores J. Schendel as Chief Scientific Officer
- Gross proceeds from capital measure of €15.9 m

Veregen®:

- Market launch in Sweden, the Czech Republic, Slovakia, Hungary, Poland, Belgium, Denmark, Finland and Canada
- Partnership agreement for the marketing of Veregen® in the UK and the Republic of Ireland
- Filing of marketing authorization applications in eight further European countries and Russia
- US partner enters promotion agreement to expand Veregen® product sales within the obstetrics, gynaecology and urology medical specialties

DC vaccines:

- US patent to protect the process for manufacturing mature, polarised dendritic cells with a patent term until 2028
- Completion of m^4 Award project to develop an optimised DC vaccine formulation for the treatment of prostate cancer
- Presentation of preclinical and initial clinical data at PIVAC-Conference, Rome, at DC 2014 Conference, Tours and publication in the scientific journal "Cancer Immunology, Immunotherapy"
- Submission of application for a Medigene sponsored clinical Phase I/II trial for the treatment ofAML

T-cell receptor (TCR) modified T-cells:

- Patent in the USA and Australia for a T-cell receptor which target the tumour-associated antigen tyrosinase
- Extension of research funding by the German Research Foundation (DFG) for the Collaborative Research Centre for adoptive T-cell therapy
- Presentation of preclinical data at SITC-Conference, USA,

TABs:

- German Ministry of Education and Research (BMBF) grant received as part of the m^4 Leading Edge Cluster Initiative
- Continuation of preclinical development with the aim of delivering proof of principle
- New research collaborations with Max Delbrück Centre for Molecular Medicine and Helmholtz Zentrum München entered
- Public funding by German Federal Ministry of Education and Research within "m4 Cluster Initiative" increased

AAVLP:

→ Preclinical study in cooperation with Pennsylvania State University for long-term protection against various HPV viruses successfully completed and final results evaluated

EndoTAG®-1:

→ Preparation of pivotal Phase III trial for TNBC by SynCore Biotechnology

RhuDex®:

→ Licensing agreement for RhuDex® in hepatology and gastroenterology
→ Falk Pharma takes over responsibility for the further development with initial focus on PBC

PRELIMINARY NOTES

Medigene develops drugs to treat cancer and autoimmune disease

Medigene AG, Planegg/Martinsried, Germany (hereinafter referred to as "Medigene"), is a biopharmaceutical company that concentrates on clinical research and development of novel drugs against cancer and autoimmune diseases and, following the acquisition of Trianta Immunotherapies GmbH in January 2014, focuses on personalized T cell-directed immunotherapies. In November 2014, Medigene announced the renaming of its wholly owned subsidiary Trianta Immunotherapies GmbH (in short "Trianta") as "Medigene Immunotherapies GmbH" (hereinafter referred to as "Medigene Immunotherapies").

Status of the product portfolio

Medigene has one approved drug on the market, Veregen®, which generates revenue. Veregen® is distributed by several partners. Through its wholly owned subsidiary Medigene Immunotherapies, Medigene has three complementary immunotherapy platforms (DC vaccines, T cell receptor- (TCR) modified T cells and anti-TCR monoclonal antibodies, TABs) with programmes in clinical development. In addition, Medigene is developing the AAVLP vaccine technology. The two clinical drug candidates, EndoTAG®-1 and RhuDex® are licensed to partners who will assume responsibility for the further clinical development.

Marketed drug

Worldwide partners: Veregen®

Veregen®, a drug for the treatment of genital warts, was developed by Medigene AG and generates revenue from royalties, supply chain and milestone payments.

Veregen® is an innovative drug formulation based on a defined extract from green tea leaves, which is obtained in a complex and specifically developed production process. In several clinical studies[1], Veregen® showed complete clearance of genital warts in more than 60% of the patients, and was very well tolerated. In its current treatment guidelines for sexually transmitted diseases, the US Center for Disease Control and Prevention recommends Sinecatechins 15% ointment (Veregen®) as a possible option for treating genital warts. In addition, Sinecatechins 10% and 15% ointment (Veregen®) were included in the current European guideline ("2012 European Guideline for the Management of Anogenital Warts") as a recommended treatment option for genital warts.

Medigene has marketing agreements for Veregen® with numerous partners worldwide in place. Medigene receives one-time upfront payments, revenues from milestone payments and from the supply of the finished product, as well as royalties on the sales of Veregen® in these countries.

Veregen® is currently available in the US and Canada, in 15 European countries (Germany, Austria, Switzerland, Spain, Serbia, the Netherlands, Norway, Sweden, the Czech Republic, Slovakia, Hungary, Poland, Belgium, Denmark, Finland) and Taiwan and has been approved in additional countries.

[1] Tatti S et al. B J Dermatol 2010; 162 (1): 176-184

The market launch in several countries is preceded by negotiations with the national authorities on the price of the drug that can be reimbursed by the statutory health insurance schemes. Medigene was notified in September 2014 that the authorities in France have decided against a reimbursement for Veregen®. Medigene is now discussing with its distribution partner in France how to proceed. Veregen® is available on the market without reimbursement in Scandinavia and the majority of Eastern European countries. In the third quarter of 2014 Medigene filed Marketing Authorization Applications in eight additional European countries (UK, Ireland, Italy, Portugal, Croatia, Latvia, Lithuania and Estonia) using the mutual recognition procedure.

In November 2014, marketing authorization application for Veregen® was submitted in Russia.

In April 2014, Medigene and the pharmaceutical company Kora Healthcare concluded an exclusive agreement for the supply and commercialisation of Veregen® in the United Kingdom and Ireland. In October 2014, Medigene's US licensee, Fougera Pharmaceuticals Inc, a Sandoz company, has signed a promotion agreement with Women's Choice Pharmaceuticals LLC (WCP), a US specialty pharmaceutical company to expand product sales within the obstetrics, gynaecology and urology medical specialties.

Immunotherapies under development

Through the acquisition of the formerly Trianta Immunotherapies GmbH (now Medigene Immunotherapies GmbH) in January 2014 as a wholly owned subsidiary, Medigene has acquired three innovative and complementary platforms in the field of immunotherapy: DC vaccines, TCR-based T cell therapy and anti-TCR monoclonal antibodies (TABs). In July 2014, Medigene secured financing with a capital measure for these therapy platforms to achieve important development milestones.

DC vaccines

The most advanced platform develops new generation antigen-tailored dendritic cell (DC) vaccines. Dendritic cells can take up antigens efficiently, process them and present them on their surface in a form that can induce antigen-specific T cells to proliferate and mature. This way T cells can recognize and eliminate antigen-bearing tumour cells. Dendritic cells can also induce natural killer cells (NK cells) to become active and attack tumour cells. Scientists of Medigene Immunotherapies have developed new, fast and efficient methods for preparing autologous (patient-specific) mature dendritic cells which have relevant characteristics to activate both T cells and NK cells. The dendritic cells can be loaded with various tumour antigens to treat different types of cancer.

DC vaccines are being evaluated in two ongoing, externally funded investigator initiated trials: a clinical Phase I/II trial in acute myeloid leukaemia (AML) at the Ludwig-Maximilian University Hospital Großhadern, Munich, in cooperation with Prof. Marion Subklewe and Prof. Wolfgang Hiddemann, and a clinical Phase II trial in prostate cancer at the Oslo University Hospital in cooperation with Prof. Gunnar Kvalheim.

In March 2014, the US Patent Office issued a patent relating to the manufacturing of mature, polarised dendritic cells. The patent has a term until 2028 and is licensed exclusively to Medigene Immunotherapies (formerly Trianta) by the Helmholtz Zentrum München-German Research Center for Environmental Health (HMGU).

In June 2014, Medigene announced that the development team for dendritic cell (DC) vaccines has successfully concluded a project for the development of an optimized formulation of a DC vaccine for the specific treatment of prostate cancer. The project was carried out at the HMGU, and was supported by the Bavarian Ministry of Economic Affairs as part of the m^4 Award. This optimized vaccine formulation will form the basis of discussions that Medigene will have with potential partners on the continued clinical development of DC vaccines for prostate cancer.

In September 2014, Medigene presented preclinical data on its DC vaccine programme at the 14th International Conference on Progress in Vaccination Against Cancer (PIVAC) Rome, Italy, at the 13th International Dendritic Cell Symposium (DC 2014) in Tours, France and in the October 2014 volume of the scientific journal "Cancer Immunology, Immunotherapy". Furthermore, Medigene's cooperation partner the University Hospital Oslo, Norway presented initial clinical data on their investigator-initated clinical PhaseII trial, currently ongoing at the University Hospital to test Medigene's DC vaccine, at the PIVAC Conference.

An application for approval of a Medigene-funded clinical Phase I/II trial for the treatment of AML patients was submitted to the Norwegian Medicines Agency in cooperation with the University Hospital in Oslo, Norway, in October 2014. Medigene plans to conduct its first company-sponsored testing of DC vaccines through this clinical trial, which will take place at the University Hospital in Oslo.

In the beginning of November 2014, initial clinical data on Medigene's DC vaccine for the treatment of AML have been presented at the SITC (Society for Immunotherapy of Cancer) 29th Annual Meeting in National Harbor/Washington D.C., USA. The poster entitled "Next generation dendritc cells for immunotherapy of acute myeloid leukemia" shows initial clinical data collected in a current investigator initiated Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML) conducted at the Ludwig-Maximilians University Hospital Großhadern, Munich, in cooperation with Prof. Marion Subklewe and Prof. Wolfgang Hiddemann.

T cell receptor (TCR)-based adoptive T cell therapy

The second platform in the field of immunotherapy aims to arm the patient's own T cells with tumour-specific T cell receptors. The receptor-modified T cells are then able to detect and efficiently kill tumour cells. This form of immunotherapy aims to overcome the patient's tolerance to cancer cells, and the tumour-induced immunosuppression in the patient, by activating and modifying the patient's T cells outside the body (ex vivo). A large army of specific T cells to fight the tumour is made available to patients within a short period of time.

Medigene is currently establishing a comprehensive library of recombinant T cell receptors and a good manufacturing practice (GMP)-compliant process for their combination with patient-derived T cells. First discussions with regulatory authorities for the preparation of first clinical trials with defined product candidates have already taken place.

In April 2014, the US Patent Office issued a patent relating to a T cell receptor against the tumour associated antigen tyrosinase. In October 2014, Medigene announced that the Australian Patent Office had issued a similar patent .The patents have a term until 2030 in the US and 2029 in Australia and have been licensed exclusively to today's Medigene Immunotherapies GmbH by Helmholtz Zentrum München (HMGU).

In July 2014, Medigene announced that today's Medigene Immunotherapies GmbH will be an active project partner in the transregional Collaborative Research Centre (SFB-TR36) "Principles and Applications of Adoptive T Cell Therapy" of the German Research Foundation (DFG). The DFG has continued the funding period of the SFB-TR36, started in 2006, for another four years. The project of the former Trianta is an integral part of the consortium that includes other projects of acclaimed scientists from Charité Universitätsmedizin Berlin, the Max Delbrück Center for Molecular Medicine (MDC), Humboldt University of Berlin (HU), Ludwig Maximilian University of Munich (LMU), Munich University of Technology (TUM) and the HMGU. The scientists' aim is to develop effective approaches to treat tumours using adoptive T cell transfer. Medigene's participation in SFB-TR36 secures established scientific and project-related cooperation with these leading German research institutions in the field of cancer immunotherapy. In particular, the promotion of technology transfer in a joint project with the HMGU facilitates access for Medigene to highly innovative preclinical tumour models for testing the efficacy of its own developed therapeutic concepts.

Moreover, at the SITC Conference in the beginning of November 2014 Medigene presented a poster entitled "Generation of tumour antigen-specific CD4+ and CD8+ T cells by simultaneous MHC-I and -II epitope presentation in vitro and in vivo". It outlined parts of Medigene's immunotherapeutic TCR program, particularly the isolation and identification of tumour-specific T cells.

Anti-TCR monoclonal antibodies (TABs)

The third product platform serves to generate monoclonal antibodies which recognise different T cells based on their T cell receptors (TABs = T cell receptor-specific antibodies). These TABs are intended to remove unwanted T cells from the body in order to treat T cell-induced diseases such as T cell leukaemia or various autoimmune diseases.

This platform has helped to produce and characterise monoclonal antibodies which are able to distinguish between different T cell receptors. Proof of technology was established in preclinical experiments.

In June 2014, it was announced that today's Medigene Immunotherapies GmbH will receive public funding for the development of its immunotherapy platform TABs for the treatment of various types of cancer and autoimmune diseases. The grant is awarded by the Federal Ministry of Education and Research, (Bundesministerium für Bildung und Forschung = BMBF) within the scope of the "m4 – Personalized Medicine and Targeted Therapies: a new Dimension of Drug Development" Munich Leading-Edge Cluster initiative. The sponsored project intends to provide evidence of the elimination of pathogenic T cells in T cell leukemia and autoimmune diseases, applying in vivo and in vitro methods with T cell receptor-specific monoclonal antibodies. The project is financed by Medigene (60%) as well as the BMBF grant (40%). In September 2014, Medigene announced an increased level of this public funding.

Moreover, in September 2014 Medigene announced that Medigene Immunotherapies entered two new research collaborations in the field of TABs. In the future, scientists of the Max Delbrück Center for Molecular Medicine (MDC) and the Helmholtz Zentrum München - German Research Center for Environmental Health, Munich (HMGU) will undertake single research and development tasks in this special field. In the context of this collaboration monoclonal antibodies for the treatment of autoimmune diseases and T cell leukemia will be tested. The in vivo data generated during the granted period will be of great value for further clinical development of this immunotherapy platform. Overall, the collaboration with both research institutions offers Medigene extended scientific synergies regarding technology transfer, infrastructure and exchange of knowledge.

AAVLP-technology

Within the AAVLP (adeno-associated virus-like particles) programme, Medigene is developing an innovative technology platform for the generation of new prophylactic and therapeutic vaccines. For this purpose, non-infectious virus-like particles derived from adeno-associated viruses (AAV) are used as epitope carriers. Epitopes delivered to the immune system in this way result in the production of specific antibodies. These antibodies in turn recognise the relevant epitope, e.g. on pathogens or mutant cancer cells, and consequently fight and/or protect against the relevant disease. Research into the use of the AAVLP technology to treat infectious diseases and cancer is being conducted by pursuing two different approaches. One is the direct integration of known epitopes. The second approach is based on the use of AAV libraries. Rather than defined epitopes, AAV libraries contain random sequences. Appropriate screening strategies enable the targeted selection of novel vaccine candidates from these libraries. The key benefit of this technology is the possibility of directly transferring the mode of action of existing therapeutically effective antibodies into an active vaccine.

A preclinical long-term study completed in cooperation with Pennsylvania State University with the aim of demonstrating long-term cross-protection against various human papilloma virus (HPV) infections has recorded positive results.

Partnered drug candidates

The following drug candidates are out-licenced to and developed by Medigene's partners:

SynCore Biotechnology Co., Ltd.: EndoTAG®-1

The clinical drug candidate EndoTAG®-1 is an innovative composition of the established cytostatic drug paclitaxel combined with neutral and positively charged lipids. Due to the positive charge, EndoTAG®-1 interacts with newly formed, negatively charged endothelial cells, which are specifically required for the growth of tumour blood vessels. The EndoTAG®-1 paclitaxel component attacks the activated endothelial cells as they divide, thus targeting the blood supply to tumours without affecting endothelial cells of healthy tissues. By doing this, EndoTAG®-1 is expected to prevent the formation of new tumour blood vessels and to inhibit tumour growth.

Medigene has successfully completed two clinical Phase II trials with EndoTAG®-1 in the indications of pancreatic cancer and triple-negative breast cancer (TNBC). Furthermore, Medigene published positive results from an Investigator-Initiated Trial (IIT) with EndoTAG®-1 in HER2-negative high-risk breast cancer at the ASCO 2013 Annual Meeting.

As part of the licence agreement with the partner SynCore Biotechnology Co., Ltd. (hereinafter referred to as "SynCore"), SynCore is fully responsible for the development and financing of the planned Phase III clinical trial with EndoTAG®-1 in the indication of TNBC, and has in turn received the global marketing rights for EndoTAG®-1. Medigene received an upfront payment from SynCore and is entitled to payments upon certain development and approval milestones as well as royalties after market approval of EndoTAG®-1.

Dr. Falk Pharma GmbH: RhuDex®

The drug candidate RhuDex® is an oral, disease modifying agent to treat autoimmune diseases. It is a CD80 antagonist that blocks undesired T-cell activation and production and therefore has an immune modulating and anti-inflammatory effect.

The safety and tolerability of RhuDex® have been demonstrated in a number of Phase I clinical trials. Medigene successfully completed a pilot Phase IIa trial in the indication rheumatoid arthritis. In 2013, Medigene outlined preparations for further clinical development of RhuDex® in the indication primary biliary cirrhosis (PBC). In March 2014, a licence agreement was completed with the pharmaceutical company Dr. Falk Pharma GmbH, Freiburg (hereinafter referred to as "Falk Pharma"), for the development and marketing rights to RhuDex® in the indications hepatology and gastroenterology. Falk Pharma will assume responsibility and all costs relating to the clinical development and marketing of RhuDex® in these therapeutic areas. Medigene received an upfront payment and future milestone payments from Falk Pharma, plus double-digit royalties on sales of RhuDex®. Falk Pharma will initially concentrate on development in primary biliary cirrhosis (PBC). Medigene retains the rights for RhuDex® in rheumatoid arthritis, psoriasis and other autoimmune diseases.

Prof. Dolores J. Schendel appointed as Chief Scientific Officer

The Supervisory Board appointed Prof. Dolores J. Schendel as Chief Scientific Officer of Medigene AG effective 1 May 2014. The former Director of the Institute of Molecular Immunology at the Helmholtz Zentrum München - German Research Center for Environmental Health, Munich (HMGU) and Managing Director of Trianta (now Medigene Immunotherapies) serves as the Executive Board member responsible for research and development at Medigene. With the appointment of Prof. Schendel, the Executive Board increased to three members.

€15.9 m from capital measure achieved

In July 2014, Medigene completed the capital measure resolved on 27 June 2014 for the funding of its immunotherapy programmes. Gross proceeds of €15.9 m were achieved by placing the maximum number of new shares and the issuance of convertible bonds.

INCOME POSITION

Revenue and other operating income

In the first nine months of 2014, Medigene's total revenue rose by 64% to €8,376 k (9M 2013: €5,121 k). The increase in the third quarter of 2014 amounted to 19%, up to €2,284 k (Q3 2013: €1,913 k). Medigene achieved sales growth of 29% to €3,672 k (9M 2013: €2,837 k) with the drug Veregen®, generating proceeds of €1,118 k on a quarterly basis (Q3 2013: €959 k). Revenue from Veregen® sales comprised royalties, revenue from product deliveries (supply chain) and milestone payments. In the first nine months of 2014, royalties fell to €1,747 k (9M 2013: €1,889 k). The increase in the third quarter of 2014 amounted to €729 k (Q3 2013: €646 k). As a result, Veregen® royalties rose again by 13% in the third quarter, following a temporary decline in previous months. At the same time, revenue from Veregen® supply chain product deliveries to sales partners increased by 63% to €1,200 k in the first nine months of 2014 (9M 2013: €735 k) and by 101% in the third quarter of the year to €364 k (Q3 2013: €181 k). Milestone payments received from partner companies were up to €725 k in the first nine months of 2014 (9M 2013: €213 k), mainly attributable to a milestone payment received as part of the agreement signed with the new marketing partner Taurus Pharma GmbH in the first quarter of 2014. In the third quarter of 2014, Medigene received milestone payments from Veregen® partners totalling €25 k (Q3 2013: €132 k).

In the first nine months of 2014, Medigene's other operating income rose by 106% to €4,704 k (9M 2013: €2,284 k). The increase in the third quarter of 2014 amounted to €1,166 k (Q3 2013: €954 k). On the one hand, this included regular, non-cash income of €1,877 k (9M 2013: €1,881 k) from the transfer of rights to Medigene's former drug Eligard®, agreed with US financial investor Cowen Healthcare Royalty Partners in 2012, and sales of RhuDex® material (active pharmaceutical ingredient, API) to partner Falk Pharma totalling €503 k (9M 2013: €0) as well as grants amounting to €64 k (9M 2013: €0). On the other hand, Medigene received cost reimbursements from partner SynCore for the development of EndoTAG®-1 amounting to €1,486 k (9M 2013: €382 k) as well as milestone payments of €742 k (9M 2013: €7 k), which essentially comprised a one-off payment in connection with the partnership agreement signed with Falk Pharma.

CONSOLIDATED INCOME STATEMENT (ABBREVIATED)

IN € K	**Q3 2014 UNAUDITED**	Q3 2013 UNAUDITED	CHANGE	**9M 2014 UNAUDITED**	9M 2013 UNAUDITED	CHANGE
Revenue Veregen®	**1,118**	**959**	**17%**	**3,672**	**2,837**	**29%**
thereof Veregen® royalties	**729**	646	13%	**1,747**	1,889	-8%
thereof Veregen® revenue from supply chain	**364**	181	101%	**1,200**	735	63%
thereof Veregen® milestone payments	**25**	132	-81%	**725**	213	>200%
Other operating income	**1,166**	954	22%	**4,704**	2,284	106%
thereof income from R&D funding	**468**	309	51%	**1,486**	382	>200%
thereof R&D milestone payments	**14**	6	133%	**742**	7	>200%
thereof other income	**684**	639	7%	**2,476**	1,895	31%
Total revenue	**2,284**	**1,913**	**19%**	**8,376**	**5,121**	**64%**
Cost of sales	**-414**	-228	82%	**-1,212**	-1,055	15%
Gross profit	**1,870**	**1,685**	**11%**	**7,164**	**4,066**	**76%**
Selling, general and administrative expenses	**-1,742**	-2,011	-13%	**-5,648**	-5,616	1%
Research and development expenses	**-1,975**	-1,673	18%	**-5,383**	-5,119	5%
Operating result	**-1,847**	**-1,999**	**-8%**	**-3,867**	**-6,669**	**-42%**
Net result for the period	**-2,804**	**-2,072**	**35%**	**-5,644**	**-7,728**	**-27%**

Cost of sales

The cost of sales amounted to €1,212 k in the first nine months of 2014 (9M 2013: €1,055 k) and to €414 k in the third quarter of 2014 (Q3 2013: €228 k). This cost was incurred for material costs and royalties for Veregen®.

Gross profit

Gross profit rose by 76% to €7,164 k in the first nine months of 2014 (9M 2013: €4,066 k) and by 11% to €1,870 k in the third quarter of the year (Q3 2013: €1,685 k).

Selling, general and administrative expenses

Selling, general and administrative expenses remained almost unchanged in the first nine months of 2014, amounting to €5,648 k (9M 2013: €5,616 k). They decreased by 13% to €1,742 k (Q3 2013: €2,011 k) in the third quarter of 2014. In the first nine months of 2014, this comprised selling expenses of €1,537 k (9M 2013: €1,773 k) as well as general and administrative expenses of €4,111 k (9M 2013: €3,843 k). General and administrative expenses increased due to one-off costs incurred in respect of the acquisition of Trianta (now Medigene Immunotherapies).

Research and development expenses

Research and development expenses rose by 5% to €5,383 k in the first nine months of 2014 (9M 2013: €5,119 k) and by 18% to €1,975 k in the third quarter of the year (Q3 2013: €1,673 k). The reduction in these expenses was mainly attributable to lower expenses for preclinical and clinical RhuDex® trials in connection with the partnership agreement signed with Falk Pharma. In contrast, personnel, patent and development expenses were up following the takeover of the former Trianta, now Medigene Immunotherapies.

EBITDA

The result on an EBITDA basis was up by 46% to €-3,269 k in the first nine months of 2014 (9M 2013: €-6,106 k) and by 10% to €-1,640 k in the third quarter of the year (Q3 2013: €-1,815 k). Medigene's EBITDA is derived from the result for the period before interest, taxes, depreciation and amortisation as well as specific non-recurring effects.

Depreciation and amortisation

Depreciation and amortisation totalled €598 k in the first nine months of 2014 (9M 2013: €563 k) and €207 k in the third quarter of 2014 (Q3 2013: €184 k).

Financial result

The financial result amounted to €-1,080 k in the reporting period (9M 2013: €-1,176 k) and essentially comprised non-cash interest expenses totalling €1,098 k (9M 2013: €1,185 k), which resulted from the valuation of financial liabilities owed to Cowen.

Foreign exchange gains/losses

On a nine-month basis, foreign exchange losses amounted to €854 k, in particular resulting from the valuation of financial liabilities owed to Cowen due to the strong US dollar exchange rate (9M 2013: profit of €227 k) or, on a quarterly basis, a book loss of €782 k was sustained (Q3 2013: book profit of €325 k).

Share of result of associates

The result from the investment in the associate Catherex, Inc. amounted to €-33 k in the first nine months of 2014 (9M 2012: €-85 k) and to €-13 k in the third quarter of 2014 (Q3 2013: €-13 k).

9-months result 2014

In the first nine months of 2014, Medigene reduced the loss for the period by 27% to €5,644 k (9M 2013: €-7,728 k). The net loss rose by 35% to €2,804 k (Q3 2013: €-2,072 k) in the third quarter of 2014.

Earnings per share

In the first nine months of 2014, the loss per share amounted to €0.49 (weighted average number of shares, basic and diluted: 11,633,933) compared with a loss of €0.81 per share in the same period of the previous year (9M 2013: weighted average number of shares, basic and diluted: 9,550,484).

FINANCIAL POSITION

Cash used by operating activities

In the first nine months of 2014, the cash outflow from operating activities decreased by 35% to €7,084 k (9M 2013: cash outflow of €10,825 k). The average monthly net cash usage was therefore €0.8 m (9M 2013: €1.2 m). The major share of the cash outflow was attributable to expenses for research and development as well as marketing and administration. Net cash used for operating activities is only of limited informative value with regard to future developments, as it is significantly influenced by one-off payments under partnership agreements and by research and development expenses, the amount of which depends on the status of projects.

Cash flow from investing activities

In the first nine months of 2014, the cash outflow from investing activities rose to €842 k (9M 2013: €42 k). The increase was mainly attributable to the purchase of property, plant and equipment for the research and development activities of the firm now called Medigene Immunotherapies. At the same time, cash and cash equivalents of €21 k were acquired from the former Trianta, now Medigene Immunotherapies.

Cash flow from financing activities

The cash inflow from financing activities amounted to €14,571 k in the first nine months of 2014 (9M 2013: €2,378 k) and comprised the proceeds from the capital increase amounting to €15.9 m and the cost of issuing Medigene shares as part of the capital increase and the acquisition of Trianta, now Medigene Immunotherapies. The cash inflow recorded in the previous year period resulted from a capital increase in connection with the strategic partnership with SynCore.

CHANGE IN CASH AND CASH EQUIVALENTS

IN € K	**Q3 2014 UNAUDITED**	Q3 2013 UNAUDITED	CHANGE	**9M 2014 UNAUDITED**	9M 2013 UNAUDITED	CHANGE
Net cash						
used by operating activities	**-1,477**	-3,322	-56%	**-7,084**	-10,825	-35%
used by investing activities	**-454**	-11	>200%	**-842**	-42	>200%
from/used by financing activities	**14,635**	-14	–	**14,571**	2,378	>200%
In-/Decrease in cash and cash equivalents	**12,704**	**-3,347**	**–**	**6,645**	**-8,489**	**–**
Cash and cash equivalents at the beginning of the period	**4,097**	14,960	-73%	**10,166**	20,113	-49%
Foreign exchange differences	**-112**	42	–	**-122**	31	–
Cash and cash equivalents at the end of the period	**16,689**	**11,655**	**43%**	**16,689**	**11,655**	**43%**

As at the reporting date of 30 September 2014, cash and cash equivalents amounted to €16,689 k (31 December 2013: €10,166 k).

ASSET POSITION

DEVELOPMENT OF ASSETS AND CAPITAL STRUCTURE

IN € K	30 SEP 2014 UNAUDITED	31 DEC 2013	CHANGE
Assets			
Property, plant and equipment and intangible assets	**36,350**	27,363	33%
Goodwill	**2,212**	2,212	0%
Financial and other non-current assets	**4,635**	4,304	8%
Investment in an associate	**2,712**	2,513	8%
Cash and cash equivalents	**16,689**	10,166	64%
Inventories and receivables	**5,476**	4,409	24%
Other current assets	**1,129**	1,688	-33%
Total assets	**69,203**	**52,655**	**31%**
Liabilities and shareholders' equity			
Shareholders' equity	**49,428**	36,276	36%
Non-current liabilities	**15,606**	11,287	38%
Current liabilities	**4,169**	5,092	-18%
Total liabilities and shareholders' equity	**69,203**	**52,655**	**31%**
Liquidity ratio in %	**24**	**19**	
Equity ratio in %	**71**	**69**	

Employees

As at the reporting date, the number of employees was 66 (31 December 2013: 51) following the integration of 16 employees from the former Trianta. The number of FTE employees (full-time equivalents) increased to 57 in the first nine months of 2014 (31 December 2013: 48). Personnel expenses amounted to €4,973 k in the reporting period (9M 2013: €4,256 k).

Related parties

Detailed information about related parties is provided on page 28 of the notes.

Segment information

For detailed segment information, please see notes, pages 26 f.

Risk report

The inherent risks to which the Group is subject are described in detail in the risk report of the published Group Management's Discussion and Analysis (MD&A) 2013. As at the closing date of 30 September 2014, no material changes to the risks described therein have occurred.

Financial risks

Since Medigene AG was founded in 1994, the Company has reported operating losses in almost every financial year, as expenses for research and development in the relevant years exceeded the corresponding revenue or gross profit. The future achievement of profitability depends on progress in terms of operations as well as Medigene's strategic decisions and is not yet secured.

At the end of the fiscal year 2013 and in the first six months of 2014, there was a risk that Medigene's cash position at the time and the operating cash flow would possibly be insufficient to cover the expected investment expenses and working capital that would be required in the foreseeable future, covering approximately 18 months, which implied that the going concern of the Company and the Group would be endangered. In view of the cash inflow of €15.9 m (gross) from the capital increase completed in July 2014, this risk no longer exists at present.

Following the capital increase implemented in July 2014, the Executive Board assumes that, on the basis of the current business plan, financing for the Company will be available until the end of 2016.

Risk management system

Medigene's management meets any risks occurring in the Group by means of a comprehensive risk management system. For a detailed description of this system, please refer to the Group Management's Discussion and Analysis (MD&A) 2013, which was published on 27 March 2014.

OPPORTUNITIES AND OUTLOOK

Financial forecast 2014

Medigene confirms its sales and income forecast for 2014. The Company expects a further double-digit percentage increase in total revenue in 2014 (2013: €7.6 m). Based on the forecasts provided by Medigene's sales partners, revenue achieved with Veregen® is likely to amount to between €5 m and €6 m (2013: €4.2 m). In addition, Medigene is set to generate revenue consisting mainly of reimbursements of development costs for EndoTAG®-1 from partner SynCore as well as non-cash payments from a transaction with Medigene's former drug Eligard® and pro rata upfront or milestone payments from partnerships. The EBITDA loss in 2014 is likely to be significantly reduced to €4 m - €6 m (2013: €8.3 m).

According to the current business assumptions, Medigene's management expects the company to be financed until the end of 2016.

Marketed drug

Veregen®

The partners anticipate market launches in further countries in 2015. Medigene expects the decision on the market approvals in Croatia, Estonia, Ireland, Italy, Latvia, Lithuania, Portugal and the UK in the first half of 2015.

Immunotherapies under development

DC vaccines

The current investigator-initiated trials (IITs) being conducted at the University Hospital in Oslo (Phase II trial in prostate cancer) and at the University Hospital in Munich (Phase I/II trial in acute myeloid leukaemia, AML) will be continued. Additionally, a compassionate use[2] programme, including patients with different types of tumor is currently ongoing at University Hospital Oslo in order to test Medigene's DC vaccine. Early clinical data on this programme will be published in the 56th American Society of Hematology (ASH) Annual Meeting in San Francisco, USA, in early December 2014. Medigene plans to initiate its own clinical AML trial before the end of 2014 and to start a further clinical trial in 2015.

TCR-modified T cells

The development of a GMP-compliant manufacturing process for the adoptive T cell therapy using TCR-modified T cells will be continued. Clinical development of the first product candidates is in preparation and first preparatory talks with the authorities have already taken place.

TABs

Preclinical development of the anti-TCR monoclonal antibodies (TABs) continues with the aim of achieving proof of principle.

AAVLP technology

The final results of the preclinical trial conducted in cooperation with Pennsylvania State University to demonstrate long-term protection against infection and cross-reactivity to various types of HPV are available. The data is positive and is expected to be published as soon as possible in the course of a scientific conference.

[2] Compassionate Use: Prescription of as-yet unapproved drugs in particularly severe cases where there are no treatment alternatives

Partnered drug candidates

The following drug candidates are out-licenced to and developed by Medigene's partners:

EndoTAG®-1

The preparation of a pivotal international Phase III trial with EndoTAG®-1 in the indication of triple-negative breast cancer (TNBC) under the responsibility of SynCore is progressing. SynCore assumes a full responsibility and full financing for this trial.

RhuDex®

Falk Pharma is conducting a comprehensive development programme with the aim of developing RhuDex® optimally in the indication primary biliary cirrhosis (PBC). The start of clinical trials will be announced at the start of each trial.

CONSOLIDATED INCOME STATEMENT

OF MEDIGENE AG FOR THE PERIODS FROM 1 JANUARY TO 30 SEPTEMBER 2014 AND 2013

IN € K	**Q3 2014 UNAUDITED**	Q3 2013 UNAUDITED	**9M 2014 UNAUDITED**	9M 2013 UNAUDITED
Product sales	**1,118**	959	**3,672**	2,837
Other operating income	**1,166**	954	**4,704**	2,284
Total revenue	**2,284**	**1,913**	**8,376**	**5,121**
Cost of sales	**-414**	-228	**-1,212**	-1,055
Gross profit	**1,870**	1,685	**7,164**	4,066
Selling expenses	**-452**	-562	**-1,537**	-1,773
General and administrative expenses	**-1,290**	-1,449	**-4,111**	-3,843
Research and development expenses	**-1,975**	-1,673	**-5,383**	-5,119
Operating result	**-1,847**	**-1,999**	**-3,867**	**-6,669**
Interest income	**6**	3	**18**	9
Interest expense	**-358**	-388	**-1,098**	-1,185
Foreign exchange gains/losses	**-782**	325	**-854**	227
Share of result of an associate	**-13**	-13	**-33**	-85
Result before tax	**-2,994**	**-2,072**	**-5,834**	**-7,703**
Taxes	**190**	0	**190**	-25
Net result for the period	**-2,804**	**-2,072**	**-5,644**	**-7,728**
Basic and diluted earnings per share in €	**-0.21**	-0.21	**-0.49**	-0.81
Weighted average number of shares outstanding (basic and diluted)	**13,385,282**	9,872,139	**11,633,933**	9,550,484

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

OF MEDIGENE AG FOR THE PERIODS FROM 1 JANUARY TO 30 SEPTEMBER 2014 AND 2013

IN € K	**Q3 2014 UNAUDITED**	Q3 2013 UNAUDITED	**9M 2014 UNAUDITED**	9M 2013 UNAUDITED
Net result for the period	**-2,804**	**-2,072**	**-5,644**	**-7,728**
Other comprehensive income				
Other comprehensive income to be reclassified to profit and loss in subsequent periods:				
Exchange differences on translation of foreign operations[1)]	**101**	-43	**111**	-29
Gain on available-for-sale financial assets[1)]	**110**	0	**278**	0
Other comprehensive income for the period, net of tax	**211**	**-43**	**389**	**-29**
Total comprehensive income for the period, net of tax	**-2,593**	**-2,115**	**-5,255**	**-7,757**

[1)] No income tax affects were incurred.

CONSOLIDATED BALANCE SHEET

OF MEDIGENE AG AS OF 30 SEPTEMBER 2014 AND 31 DECEMBER 2013

ASSETS

IN € K		30 SEP 2014 UNAUDITED	31 DEC 2013
A. Non-current assets			
I.	Property, plant and equipment	**922**	405
II.	Intangible assets	**35,428**	26,958
III.	Goodwill	**2,212**	2,212
IV.	Financial assets	**4,313**	3,929
V.	Investment in associates	**2,712**	2,513
VI.	Other assets	**322**	375
Total non-current assets		**45,909**	**36,392**
B. Current assets			
I.	Inventories	**3,792**	3,046
II.	Trade accounts receivable	**1,684**	1,363
III.	Cash and cash equivalents	**16,689**	10,166
IV.	Other assets	**1,129**	1,688
Total current assets		**23,294**	**16,263**
Total assets		**69,203**	**52,655**

LIABILITIES AND SHAREHOLDERS' EQUITY

A. Shareholders' equity			
I.	Subscribed capital	**13,919**	9,872
II.	Additional paid-in capital	**387,946**	373,586
III.	Accumulated deficit	**-352,651**	-347,007
IV.	Other reserves	**214**	-175
Total shareholders' equity		**49,428**	**36,276**
B. Non-current liabilities			
I.	Financial liabilities	**10,490**	10,356
II.	Pension obligations	**297**	304
III.	Other financial liabilities	**2,518**	291
IV.	Deferred income	**240**	336
V.	Deferred taxes	**2,061**	0
Total non-current liabilities		**15,606**	**11,287**
C. Current liabilities			
I.	Trade accounts payable	**627**	1,419
II.	Other financial liabilities	**3,486**	3,651
III.	Deferred income	**56**	22
Total current liabilities		**4,169**	**5,092**
Total liabilities		**19,775**	**16,379**
Total liabilities and shareholders' equity		**69,203**	**52,655**

CONSOLIDATED STATEMENT OF CASH FLOWS

OF MEDIGENE AG FOR THE PERIODS FROM 1 JANUARY TO 30 SEPTEMBER 2014 AND 2013

IN € K	**Q3 2014 UNAUDITED**	Q3 2013 UNAUDITED	**9M 2014 UNAUDITED**	9M 2013 UNAUDITED
Cash flow from operating activities				
Net result for the period before taxes	**-2,994**	**-2,072**	**-5,834**	**-7,703**
Non-cash adjustments to reconcile net result before tax to net cash flows:				
Share-based compensation	**6**	11	**19**	33
Other non-cash income	**-623**	-623	**-1,870**	-1,870
Depreciation and amortisation	**207**	184	**598**	563
Loss on disposal of property, plant and equipment	**2**	0	**2**	0
Interest income	**-6**	-3	**-18**	-9
Interest expense	**358**	388	**1,098**	1,185
Changes in:				
Inventories	**118**	25	**-746**	-1,265
Other assets and accounts receivable	**1,005**	-522	**199**	-679
Trade accounts payable	**-442**	-694	**-792**	-395
Other liabilities and deferred income	**878**	-29	**223**	-114
Income tax expense	**0**	0	**0**	-663
Share of result of associates	**13**	13	**33**	85
Subtotal	**-1,478**	**-3,322**	**-7,088**	**-10,832**
Interest received	**1**	0	**4**	7
Net cash used by operating activities	**-1,477**	**-3,322**	**-7,084**	**-10,825**
Cash flow from investing activities				
Purchase of property, plant and equipment	**-454**	-11	**-863**	-42
Cash and cash equivalents acquired with subsidiary	**0**	0	**21**	0
Net cash used by investing activities	**-454**	**-11**	**-842**	**-42**
Net cash used by financing activities				
Proceeds from capital increase	**15,900**	0	**15,900**	2,406
Expenses on shares issued	**-1,265**	-14	**-1,329**	-28
Cash flow from/used by financing activities	**14,635**	**-14**	**14,571**	**2,378**
Decrease in cash and cash equivalents	**12,704**	**-3,347**	**6,645**	**-8,489**
Cash and cash equivalents at the beginning of the period	**4,097**	14,960	**10,166**	20,113
Foreign exchange differences	**-112**	42	**-122**	31
Cash and cash equivalents at the end of the period	**16,689**	**11,655**	**16,689**	**11,655**

CONSOLIDATED STATEMENT OF CHANGES IN SHARE-HOLDERS' EQUITY

OF MEDIGENE AG FOR THE PERIODS FROM 1 JANUARY TO 30 SEPTEMBER 2014 AND 2013

IN € K	NUMBER OF SHARES	SUBSCRIBED CAPITAL	CAPITAL RESERVE	ACCUMULATED DEFICIT	CURRENCY TRANSLATION	FINANCIAL ASSETS	TOTAL SHAREHOLDERS' EQUITY
Balance 1 Jan 2013	**37,082,758**	**37,082**	**343,938**	**-336,724**	**-123**	**-6**	**44,167**
Net result for the period				**-7,728**			**-7,728**
Other comprehensive income					-29	0	-29
Comprehensive income							**-7,757**
Shares issued	2,405,800	2,406	0				2,406
Expenses on shares issued			-14				-14
Share capital reduction	-29,616,419	-29,616	29,616				0
Expenses on share capital reduction			-14				-14
Share-based compensation			33				33
Balance 30 Sep 2013, unaudited	**9,872,139**	**9,872**	**343,559**	**-344,452**	**-152**	**-6**	**38,821**
Balance 1 Jan 2014	**9,872,139**	**9,872**	**373,586**	**-347,007**	**-177**	**2**	**36,276**
Net result for the period				**-5,644**			**-5,644**
Other comprehensive income					**111**	**278**	**389**
Comprehensive income							**-5,255**
Shares issued	**3,028,981**	**3,029**	**12,871**				**15,900**
Expenses on shares issued			**-1,265**				**-1,265**
Shares issued from business combinations	**1,017,811**	**1,018**	**2,799**				**3,817**
Expenses on shares issued from business combinations			**-64**				**-64**
Share-based compensation			**19**				**19**
Balance 30 Sep 2014, unaudited	**13,918,931**	**13,919**	**387,946**	**-352,651**	**-66**	**280**	**49,428**

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

OF MEDIGENE AG, PLANEGG/MARTINSRIED, FOR THE PERIOD FROM 1 JANUARY TO 30 SEPTEMBER 2014

A. DESCRIPTION OF BUSINESS ACTIVITY, INFORMATION ABOUT THE COMPANY

Medigene AG, Planegg/Martinsried, Germany (hereinafter referred to as "Medigene"), is a biopharmaceutical company that concentrates on clinical research and development of novel drugs against cancer and autoimmune diseases and, following the acquisition of Trianta Immunotherapies GmbH in January 2014, focuses on personalized T cell-directed immunotherapies. In November 2014 Medigene announced the renaming of its wholly owned subsidiary Trianta Immunotherapies GmbH (in short "Trianta") to Medigene Immunotherapies GmbH (hereinafter referred to as "Medigene Immunotherapies").

The Group's main activities are described in note *I) "Segment reporting"* of these notes to the interim consolidated financial statements.

Medigene AG has been listed since June 2000 (German Stock Exchange: Regulated Market, Prime Standard; WKN 1AX 3WO; code MDG1).

B. ACCOUNTING AND VALUATION PRINCIPLES

Basic principles for the preparation of interim financial statements

As a parent company geared to the capital markets within the meaning of Article 4 of Regulation (EC) No. 1606/2002, Medigene AG prepares its consolidated financial statements in accordance with the International Financial Reporting Standards (IFRS) as applicable in the EU. These unaudited consolidated quarterly financial statements were prepared in accordance with IAS standard 34 "Interim Financial Reporting", which has been adopted by the EU.

The Company's Executive Board is of the opinion that these quarterly financial statements reflect all business transactions required to present the assets, financial and income situation at the end of the periods which ended on 30 September 2014 and 2013.

This interim financial statement does not include the full information required to prepare annual financial statements. Therefore, these interim financial statements should be read in connection with the consolidated financial statements for 2013.

This interim financial statement of Medigene AG was approved for publication by Medigene's Executive Board on 20 November 2014.

Financial risks

Since Medigene AG was founded in 1994, the Company has reported operating losses in almost every financial year, as expenses for research and development in the relevant years exceeded the corresponding revenue or gross profit. The future achievement of profitability depends on progress in terms of operations as well as Medigene's strategic decisions and is not yet secured.

At the end of the financial year 2013 and after the first six months of 2014, there was a risk that Medigene's cash position at the time and the operating cash flow would possibly be insufficient to cover the expected investment expenses and working capital that would be required in the foreseeable future, covering approximately 18 months, which implied that the going concern of the Company and the Group would be endangered. In view of the cash inflow of €15.9 m (gross) from the capital increase completed in July 2014, this risk no longer exists at present.

Following the capital increase completed in July 2014, the Executive Board assumes that, on the basis of the current business plan, financing for the Company will be available until the end of 2016.

Changes in accounting, valuation, and reporting principles

The accounting, valuation and reporting principles applied for these interim consolidated financial statements correspond to those applied by Medigene for the consolidated annual financial statements for 2013, with the exception of the new announcements explained below, which have been applied since 1 January 2014.

IFRS 10 *Consolidated Financial Statements*

IFRS 10 replaces the provisions of the previous IAS 27 *Consolidated and Separate Financial Statements* on group accounting and redefines the term "control". IFRS 10 had no impact on the consolidation of the Group's interests.

IFRS 11 *Joint Arrangements*

IFRS 11 replaces IAS 31 *Interests in Joint Ventures* and defines the term "joint control". The term "control" as used in this definition corresponds to the definition in IFRS 10. IFRS 11 had no impact on the accounting for the Company's existing cooperation, licensing and development agreements.

IFRS 12 *Disclosure of Interests in Other Entities*

IFRS 12 describes the requirements in terms of disclosures about an entity's interests in subsidiaries, joint arrangements and associates. None of these disclosure requirements apply to abbreviated interim consolidated financial statements, unless significant events and business transactions occurring in the interim reporting period require disclosure. Consequently, the Group has made no such disclosures.

Group companies

In addition to the parent company, Medigene AG in Planegg/Martinsried, Germany, the Group includes wholly-owned subsidiary Medigene, Inc., San Diego, California, USA, which was acquired in 2001 and, since its acquisition in January 2014, wholly-owned subsidiary Medigene Immunotherapies GmbH (the former Trianta), Munich, Germany. Medigene, Inc. holds 40.40% of the shares in Catherex, Inc., Philadelphia, Pennsylvania, USA, which is accounted for at equity as an associate. Furthermore, Medigene, Inc. has a 38.95% stake in Aettis, Bala Cynwyd, PA, USA, a new company established as a result of part of Catherex, Inc. being spun off.

This aside, Medigene AG held no other shares in affiliated companies, associates or joint ventures as at 30 September 2014. The financial statements of the companies consolidated have been prepared in accordance with standardised accounting and valuation principles. All intercompany revenue, expenses and income as well as receivables, payables and accruals of the companies consolidated were eliminated during consolidation.

C. NOTES TO THE INCOME STATEMENT

Revenue and other income

In the first nine months of 2014, Medigene's total revenue rose by 64% to €8,376 k (9M 2013: €5,121 k). The increase in the third quarter of 2014 amounted to 19%, up to €2,284 k (Q3 2013: €1,913 k). Medigene achieved sales growth of 29% to €3,672 k (9M 2013: €2,837 k) with the drug Veregen®, generating proceeds of €1,118 k on a quarterly basis (Q3 2013: €959 k). Revenue from Veregen® sales comprised royalties, revenue from product deliveries (supply chain) and milestone payments. In the first nine months of 2014, royalties fell to €1,747 k (9M 2013: €1,889 k). The increase in the third quarter of 2014 amounted to €729 k (Q3 2013: €646 k). As a result, Veregen® royalties rose again by 13% in the third quarter, following a temporary decline in previous months. At the same time, revenue from Veregen® supply chain product deliveries to sales partners increased by 63% to €1,200 k in the first nine months of 2014 (9M 2013: €735 k) and by 101% in the third quarter of the year to €364 k (Q3 2013: €181 k). Milestone payments received from partner companies were up to €725 k in the first nine months of 2014 (9M 2013: €213 k), mainly attributable to a milestone payment received as part of the agreement signed with the new marketing partner Taurus Pharma GmbH in the first quarter of 2014. In the third quarter of 2014, Medigene

received milestone payments from Veregen® partners totalling €25 k (Q3 2013: €132 k).
In the first nine months of 2014, Medigene's other operating income rose by 106% to €4,704 k (9M 2013: €2,284 k). The increase in the third quarter of 2014 amounted to €1,166 k (Q3 2013: €954 k). On the one hand, this included regular, non-cash income of €1,877 k (9M 2013: €1,881 k) from the transfer of rights to Medigene's former drug Eligard®, agreed with US financial investor Cowen Healthcare Royalty Partners in 2012, and sales of RhuDex® material (active pharmaceutical ingredient, API) to partner Falk Pharma totalling €503 k (9M 2013: €0) as well as grants amounting to €64 k (9M 2013: €0). On the other hand, Medigene received cost reimbursements from partner SynCore for the development of EndoTAG®-1 amounting to €1,486 k (9M 2013: €382 k) as well as milestone payments of €742 k (9M 2013: €7 k), which essentially comprised a one-off payment in connection with the partnership agreement signed with Falk Pharma.

Cost of sales

The cost of sales amounted to €1,212 k in the first nine months of 2014 (9M 2013: €1,055 k) and to €414 k in the third quarter of 2014 (Q3 2013: €228 k). This cost was incurred for material costs and royalties for Veregen®.

Gross profit

Gross profit rose by 76% to €7,164 k in the first nine months of 2014 (9M 2013: €4,066 k) and by 11% to €1,870 k in the third quarter of the year (Q3 2013: €1,685 k).

Selling, general and administrative expenses

Selling, general and administrative expenses remained almost unchanged in the first nine months of 2014, amounting to €5,648 k (9M 2013: €5,616 k). They decreased by 13% to €1,742 k (Q3 2013: €2,011 k) in the third quarter of 2014. In the first nine months of 2014, this comprised selling expenses of €1,537 k (9M 2013: €1,773 k) as well as general and administrative expenses of €4,111 k (9M 2013: €3,843 k). General and administrative expenses increased due to one-off costs incurred in respect of the acquisition of Trianta (now "Medigene Immunotherapies").

Research and development expenses

Research and development expenses rose by 5% to €5,383 k in the first nine months of 2014 (9M 2013: €5,119 k) and by 18% to €1,975 k in the third quarter of the year (Q3 2013: €1,673 k). The reduction in these expenses was mainly attributable to lower expenses for preclinical and clinical RhuDex® trials in connection with the partnership agreement signed with Falk Pharma. In contrast, personnel, patent and development expenses were up following the takeover of the former Trianta, now Medigene Immunotherapies.

D. NOTES TO THE BALANCE SHEET

Subscribed capital

The subscribed capital rose by €4,047 k from €9,872 k to €13,919 k as at 30 September 2014 as a result of the shares issued for the capital increase placed in July 2014 and in connection with the former acquisition of Trianta (now "Medigene Immunotherapies"). The subscribed capital was divided into 13,918,931 no-par registered shares as at 30 September 2014, of which approximately 77% were in free float as at the reporting date.

Intangible assets

As at 30 September 2014, intangible assets amounted to €35,428 k. The change in reported intangible assets compared with 31 December 2013 was due to the acquisition of the former Trianta on the one hand and to planned amortisation of patents and product licences on the other.

Financial assets

Financial assets amounted to €4,313 k as at the reporting date. They essentially comprised the shares held in Immunocore Ltd., which were valued at fair value and amounted to €3,813 k as at 30 September 2014 (31 December 2013: €3,533 k). Medigene's previously held shares in Immunocore Ltd. amounted to 3,373,318 shares. They were A ordinary shares, which corresponded in defined cases to voting rights of 17.45% and were limited to a maximum value of £2.8 m. In June 2014, Medigene converted its shares in Immunocore Ltd. into a share class which offers a potential increase in value. As a result of the new share structure, Medigene's shareholding now comprises 64,815 ordinary shares, which corresponded to a share of 3.07%. These shares will directly participate in the future enterprise value. Following the exercise of option rights to Immunocore shares by employees of Immunocore, Medigene's shareholding decreased to 2.93% as at 30 September 2014 while the number of shares held remained unchanged.

A revaluation of the shares produced a profit of €278 k, which was reported under "gain on available-for-sale financial assets" in the consolidated statement of comprehensive income. The shares in Immunocore Ltd. are classed as financial assets available for sale and included in level three of the hierarchy of fair values of financial instruments. The fair value of these shares was determined with the help of an external expert. This figure corresponds to the current fair value according to the best possible estimates of the Executive Board.

Investment in associates

As at the reporting date of 30 September 2014, the investment in associates amounted to €2,712 k (31 December 2013: €2,513 k). A part of Catherex, Inc. was hived off into the newly established company, Aettis, in 2014. Some of the Catherex, Inc. patents were transferred to Aettis. Medigene, Inc. holds 40.40% of the shares in Catherex, Inc. and 38.95% of the shares in Aettis as at 30 September 2014. The total value of the shares now refers to the investment in Catherex (€2,712 k) and Aettis (€0).

Current liabilities

Compared with 31 December 2013, current liabilities decreased by €923 k from €5,092 k to €4,169 k as at 30 September 2014. This decrease mainly resulted from a reduction in trade accounts payable. Other financial liabilities comprise the €1,142 k short-term portion of the liability arising from the assignment of a 2% share of the Eligard® net sales to Cowen and the liability for future milestone payments to the shareholders of the former Trianta totalling €454 k (Trianta is now called "Medigene Immunotherapies").

Non-current liabilities

Non-current liabilities include the long-term portion of the liability arising from the assignment of 2% of the Eligard® net sales to Cowen. This item amounted to €10,490 k as at the reporting date and will be amortised over the remaining life of the Eligard® patent, which is now approximately seven years. The amount includes liabilities with a term of one to five years (€6,214 k) and more than five years (€4,276 k). In addition, it includes deferred tax amounting to €2,061 k resulting from the acquisition of the former Trianta (now "Medigene Immunotherapies") and a long-term portion of the liability for payments due to shareholders of the former Trianta related to future milestone achievements of €2,221 k.

E. BUSINESS COMBINATIONS

On 27 January 2014, Medigene AG announced the acquisition of Trianta Immunotherapies GmbH (now "Medigene Immunotherapies GmbH"), a new company founded by Helmholtz Zentrum in Munich (HMGU), Germany. As part of this acquisition, Medigene acquired 100% of the shares. The former shareholders of Trianta received 1,017,811 new Medigene shares issued, worth approx. €3.8 m, and will receive further payments in stages up to a maximum amount of €5.9 m upon achieving future milestones, either in the form of additional Medigene shares or in cash. Medigene Immunotherapies has three highly innovative complementary immunotherapy platforms that complement each other and encompass programmes in clinical development for the treatment of different types of cancer.

Medigene Immunotherapies has its registered office in Lochhamer Strasse 11, Planegg/Martinsried, Germany. As at 30 September 2014, the number of employees totalled 16. Prof. Dolores J. Schendel, Managing Director of the former Trianta, was appointed to the Executive Board of Medigene AG with responsibility for research and development with effect from 1 May 2014.

The acquisition is treated in accordance with IFRS 3 Business Combinations. In view of the still incomplete information about the fair value of the share of the consideration assigned (future milestone payments) and the fair value of the assets identified upon acquisition and the liabilities assumed, it was not possible to carry out a final purchase price allocation.

The provisional estimate of the purchase price (assigned consideration) totalled €6,492 k and comprised the following: fair value of the shares issued (€3,817 k) and the liability for future milestone payments to the former Trianta shareholders, which was valued at the provisional market price of €2,675 k in total. The fair value of the shares issued corresponds to the XETRA closing price (German Stock Exchange, Frankfurt) of Medigene's shares on the date of the acquisition, which was 27 January 2014. The liability vis-à-vis the former Trianta shareholders, which may provisionally fall due in the period from 2014 to 2016, is linked to the further progress of the development projects conducted by Medigene Immunotherapies and conditional on the achievement of specific milestones.

CONSIDERATION TRANSFERRED

IN € K

Shares issued at fair value		**3,817**
Number of shares issued	**1,017,811**	
Fair value per share (in €)	**3.75**	
Liability for future milestone payments at fair value (provisional)		**2,675**
Total consideration transferred (provisional)		**6,492**

The assets acquired and liabilities assumed from Medigene Immunotherapies were identified on a provisional basis. On the acquisition date, they comprised the following: cash and cash equivalents of €21 k and intangible assets in connection with the development projects conducted by the former Trianta, which were valued at the estimated market price of €8,722 k, as well as deferred tax of €2,251 k.

ACQUIRED ASSETS IDENTIFIED AND TRIANTA LIABILITIES ASSUMED

IN € K

Current assets at fair value (cash and cash equivalents)	**21**
Intangible assets at fair value (provisional)	**8,722**
Deferred tax (provisional)	**-2,251**
Total acquired assets identified and liabilities assumed (provisional)	**6,492**

Since the purchase price allocation was not finalised at the time of preparing these interim consolidated financial statements, no goodwill was reported on the balance sheet. It is expected that the acquisition of this company will release certain synergies, which will facilitate taking the Company's technologies and drug candidates through clinical development with the aim of improving the lives of critically ill patients.

The cost directly incurred for the acquisition of the former Trianta (now Medigene Immunotherapies) of €796 k was expensed and reported under general and administrative expenses. The cost of issuing shares totalling €64 k was directly offset in shareholders' equity.

ACTUAL CASH FLOW RESULTING FROM THE ACQUISITION

IN € K

Net cash acquired with subsidiary (included in the cash flow from investing activities)	**21**
Cost directly incurred for the acquisition of subsidiary [1] (included in the cash flow from operating activities)	**-796**
Transaction cost attributable to issuing shares (included in the cash flow from financing activities)	**-64**
Total cash outflow	**-839**

[1] Of this figure, €512 k was incurred in 2013.

Since the date of acquisition, Medigene Immunotherapies contributed €64 k to other operating income, and €853 k net loss to consolidated result before tax. Assuming that Medigene Immunotherapies had already been included in the scope of consolidation on 1 January 2014, there would have been no additional influence on consolidated income.

The Company concluded a profit and loss transfer agreement with the former Trianta (now "Medigene Immunotherapies"), in order to set up an affiliation for tax purposes. Since the affiliation came into effect on 1 May 2014, deferred tax assets can be recognised in relation to loss carry forward accumulated by Medigene AG up to the amount of the deferred tax liabilities of Medigene Immunotherapies assumed as part of the acquisition, considering statutory limitations. The resultant deferred tax benefit was reported in the third quarter of 2014, in accordance with IAS 12.67.

F. SEGMENT REPORTING

Business units

The Group is organised into two main business units: "Marketed Products" and "Drug Candidates".

SEGMENT REPORTING BY BUSINESS UNITS

IN € K	MARKETED PRODUCTS	DRUG CANDIDATES	TOTAL SEGMENTS	RECON-CILIATION[1]	TOTAL
Q3 2014					
Revenue with external customers	**1,118**	**0**	**1,118**	**0**	**1,118**
Other income	**629**	**535**	**1,164**	**2**	**1,166**
Inter-segment sales[2]	**0**	**0**	**0**	**0**	**0**
Total revenue	**1,747**	**535**	**2,282**	**2**	**2,284**
Segment operating result[3]	**393**	**-2,242**	**-1,849**	**2**	**-1,847**
Depreciation and amortisation	**-1**	**-198**	**-199**	**-8**	**-207**
Share of result of associates	**0**	**0**	**0**	**-13**	**-13**
Assets					
Investment in associates	**0**	**0**	**0**	**2,712**	**2,712**
Segment investments[4]	**0**	**437**	**437**	**17**	**454**
Segment assets[5]	**5,476**	**37,640**	**43,116**	**26,087**	**69,203**
Segment liabilities[6]	**0**	**296**	**296**	**19,479**	**19,775**
Q3 2013					
Revenue with external customers	959	0	959	0	959
Other income	631	320	951	3	954
Inter-segment sales[2]	0	0	0	0	0
Total revenue	**1,590**	**320**	**1,910**	**3**	**1,913**
Segment operation result[3]	**186**	**-2,188**	**-2,002**	**3**	**-1,999**
Depreciation and amortisation	0	-141	-141	-43	-184
Share of result of associates	0	0	0	-13	-13
Assets					
Investment in associates	0	0	0	2,581	2,581
Segment investments[4]	0	0	0	11	11
Segment assets[5]	**4,777**	**29,242**	**34,019**	**20,058**	**54,077**
Segment liabilities[6]	**0**	**424**	**424**	**14,784**	**15,208**

[1] Segment reconciliation includes information that can be allocated to neither the "Marketed Products" segment nor the "Drug Candidates" segment, as it does not depict any activity of its own.

[2] Inter-segment sales are eliminated for consolidation purposes.

[3] Segment operating result does not include any interest income (Q3 2014: €6 k; Q3 2013: €3 k), any interest expense (Q3 2014: €358 k; Q3 2013: €388 k), any foreign exchange gains/losses (Q3 2014: €-782 k; Q3 2013: €325 k), any share of gain or loss of an associate (Q3 2014: €-13 k; Q3 2013: €-13 k).

[4] Segment investments relate to additions to property, plant and equipment, and intangible assets.

SEGMENT REPORTING BY BUSINESS UNITS

IN € K	MARKETED PRODUCTS	DRUG CANDIDATES	TOTAL SEGMENTS	RECON-CILIATION[1]	TOTAL
9M 2014					
Revenue with external customers	**3,672**	**0**	**3,672**	**0**	**3,672**
Other income	**1,880**	**2,820**	**4,700**	**4**	**4,704**
Inter-segment sales[2]	**0**	**0**	**0**	**0**	**0**
Total revenue	**5,552**	**2,820**	**8,372**	**4**	**8,376**
Segment operating result[3]	**1,008**	**-4,879**	**-3,871**	**4**	**-3,867**
Depreciation and amortisation	**-1**	**-490**	**-491**	**-107**	**-598**
Share of result of associates	**0**	**0**	**0**	**-33**	**-33**
Assets					
Investment in associates	**0**	**0**	**0**	**2,712**	**2,712**
Segment investments[4]	**0**	**641**	**641**	**222**	**863**
Segment assets[5]	**5,476**	**37,640**	**43,116**	**26,087**	**69,203**
Segment liabilities[6]	**0**	**296**	**296**	**19,479**	**19,775**
9M 2013					
Revenue with external customers	2,837	0	2,837	0	2,837
Other income	1,884	395	2,279	5	2,284
Inter-segment sales[2]	0	0	0	0	0
Total revenue	**4,721**	**395**	**5,116**	**5**	**5,121**
Segment operation result[3]	**131**	**-6,804**	**-6,673**	**4**	**-6,669**
Depreciation and amortisation	-1	-432	-433	-130	-563
Share of result of associates	0	0	0	-85	-85
Assets					
Investment in associates	0	0	0	2,581	2,581
Segment investments[4]	0	0	0	42	42
Segment assets[5]	**4,777**	**29,242**	**34,019**	**20,058**	**54,077**
Segment liabilities[6]	**0**	**424**	**424**	**14,784**	**15,208**

[1] Segment reconciliation includes information that can be allocated to neither the "Marketed Products" segment nor the "Drug Candidates" segment, as it does not depict any activity of its own.

[2] Inter-segment sales are eliminated for consolidation purposes.

[3] Segment operating result does not include any interest income (9M 2014: €18 k; 9M 2013: €9 k), any interest expense (9M 2014: €1,098 k; 9M 2013: €1,185 k), any foreign exchange gains/losses (9M 2014: €-854 k; 9M 2013: €227 k), any share of loss of an associate (9M 2014: €33 k; 9M 2013: €85 k).

[4] Segment investments relate to additions to property, plant and equipment, and intangible assets.

[5] Segment assets under reconciliation include non-current assets (9M 2014: €8,269 k; 9M 2013: €6,906 k), cash and cash equivalents (9M 2014: €16,689 k; 9M 2013: €11,655 k) and other current assets (9M 2014: €1,129 k; 9M 2013: €1,497 k).

[6] Segment liabilities under reconciliation include non-current liabilities (9M 2014: €15,366 k; 9M 2013: €11,326 k), trade accounts payable and other financial liabilities (9M 2014: €4,113 k; 9M 2013: €3,458 k).

Revenue earned by the individual segments is generated by external business relationships.

Transfer prices between the business units and regions are determined on the basis of the usual market terms among third parties.

The segments are composed as follows:

Marketed products

- Veregen® for the treatment of genital warts
- Eligard® for the treatment of prostate cancer (the 2% sales share has been transferred to Cowen)

Drug candidates & technologies

- Immunotherapies
- EndoTAG®-1 for the treatment of solid tumours
- RhuDex® for the treatment of autoimmune diseases
- AAVLP technology

G. OTHER NOTES

Related parties

The parties deemed to be related are entities and individuals who can be significantly influenced by the Company or can exert significant influence on the Company. Related parties are the Company's Executive Board and Supervisory Board as well as the associates Catherex, Inc. and Aettis as well as partner company and shareholder SynCore Biotechnology Co., Ltd. (hereinafter referred to as "SynCore").

Dr. Frank Mathias, Chief Executive Officer of Medigene AG, and Peter Llewellyn-Davies, Chief Financial Officer of Medigene AG, were appointed to the Board of Directors of Catherex, Inc. and Aettis. Medigene, Inc. granted a fixed-rate loan to Catherex, Inc., which was increased to €346 k (31 December 2013: €242 k) in the reporting period. €33 k of this loan was transferred to Aettis.

Medigene AG received cost reimbursements of €1,486 k for EndoTAG®-1 from its partnership with SynCore (9M 2013: €0) as well as realised deferred milestones amounting to €42 k (9M 2013: €7 k). For Veregen®, Medigene AG received neither milestone payments nor revenue from supply chain activities with SynCore in the first nine months of 2014 (9M 2013: milestone payments €100 k; revenue from supply chain activities €94 k).

The remuneration and shareholdings of the Company's Executive Board and Supervisory Board members are itemised for each member of these boards under *H) "Executive Board and Supervisory Board".*

Contingent liabilities

For the contingent liabilities listed below, no provisions were recognised, as the risk of them being utilized is deemed unlikely.

In 2004, Medigene concluded an agreement with the insolvency administrator of MBT (formerly "Munich Biotechnology") under which payments by Medigene to the insolvency administrator were agreed in the event of certain milestones being achieved. These included a milestone payment if a clinical Phase III trial would be initiated. In connection with signing an agreement with SynCore in July 2012, the Company has achieved a settlement with the insolvency administrator which stipulates that Medigene will no longer make milestone payments but instead must only transfer a minor percentage of the income generated with EndoTAG®-1. The amount is gradually payable up to a total amount of €11 m. From the Company management's point of view, no accruals need to be recognised for this purpose at present, because the relevant payments will only be due following the achievement of specific events.

The Company leases office and laboratory facilities, office furnishings, laboratory equipment, and vehicles. These constitute operating leases, as the contractual agreement does not transfer any risks and rewards to the Group. The conditions, rental increase clauses and extension options of lease agreements vary.

The Group has a notice period of one month to six years for these lease agreements, depending on the contract.

H. EXECUTIVE BOARD AND SUPERVISORY BOARD

REMUNERATION, "DIRECTORS' HOLDINGS" AND NOTE ON SUBSCRIPTION RIGHTS

IN € K OR NUMBERS	REMUNERATION	SHARES		OPTIONS	
	30 SEP 2014	**30 SEP 2014**	31 DEC 2013	**30 SEP 2014**	31 DEC 2013
Prof. Horst Domdey Chairman, Co-founder	**33**	**39,125**	39,125	**0**	0
Dave Lemus Vice Chairman of Supervisory Board	**28**	**0**	0	**0**	0
Dr. Yita Lee Supervisory Board member	**22**	**0**	0	**0**	0
Total Supervisory Board	**83**	**39,125**	**39,125**	**0**	**0**
Dr. Frank Mathias Chief Executive Officer[1)]	**453**	**1,499**	1,499	**49,375**	49,375
Peter Llewellyn-Davies Chief Financial Officer[1)]	**333**	**4,000**	3,000	**9,375**	9,375
Prof. Dolores J. Schendel Chief Scientific Officer[1)] (since 1 May 2014)	**181**	**611,704[2)]**	–	**0**	–
Total Executive Board[1)]	**967**	**617,203**	**4,499**	**58,750**	**58,750**

[1)] The Executive Board remuneration comprises fixed remuneration, variable performance-related remuneration based on setting up accruals (without discounting) in the event of 100% payment and fringe benefits (pension expenses and vehicle leasing).

[2)] Through DJSMontana Holding GmbH.

RESPONSIBILITY STATEMENT

To the best of our knowledge and in accordance with the applicable reporting principles, the consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the Group, and the Group management report includes a fair review of the development and performance of the business and the position of the Group, together with a description of the principal opportunities and risks associated with the expected development of the Group.

Planegg/Martinsried, 20 November 2014

The Executive Board



Dr. Frank Mathias

Peter Llewellyn-Davies

Prof. Dolores J. Schendel

FINANCIAL CALENDAR

25 March 2015
Annual Report 2014
Analysts and Press Conference Call

TRADEMARKS

EndoTAG®
is a trademark of Medigene AG

Medigene®
is a trademark of Medigene AG

Medigene Immunotherapies™
is a trademark of Medigene Immunotherapies GmbH

Polyphenon E®
is a trademark of Mitsui Norin Co, Ltd

RhuDex®
is a trademark of Medigene AG

Trianta™
is a trademark of Medigene Immunotherapies GmbH

Trianta Immunotherapies™
is a trademark of Medigene Immunotherapies GmbH

Veregen®
is a trademark of Medigene AG

These trademarks may be held or licensed for specific countries.

IMPRINT

Published by

Medigene AG
Lochhamer Straße 11
82152 Planegg/Martinsried
Germany
T +49 (89) 20 00 33-29 0
F +49 (89) 20 00 33-29 20

Contact

Public & Investor Relations
Julia Hofmann, Anja Clausnitzer
T +49 (89) 20 00 33-33 01
investor@medigene.com
public.relations@medigene.com

DISCLAIMER

This quarterly report contains forward-looking statements that are based on certain assumptions and expectations made by the management of Medigene AG at the time of its publication, These forward-looking statements are therefore subject to unpredictable risks and uncertainties, so there is no guarantee that these assumptions and expectations will turn out to be accurate, Many of those risks and uncertainties are determined by factors that are beyond the control of Medigene AG and cannot be gauged with any certainty at this point in time, This includes future market conditions and economic developments, the behaviour of other market participants, the achievement of targeted synergy effects as well as legal and political decisions, Medigene AG cannot preclude that actual results may differ substantially from those expectations expressed in or implied by the forward-looking statements, Medigene AG does not intend or assume any obligation to update any forward-looking statements to reflect events or circumstances after the date of this annual report,

The English version of the quarterly report is a translation of the original German version; in the event of variances, the German version shall take precedence over the English translation,

www.medigene.com